N@N

Keay Nakae Reiterated (ARWR) at Strong Buy and Held Target at $60 on, Aug 8th, 2023

Keay Nakae of Chardan Capital, Reiterated "Arrowhead Pharmaceuticals, Inc." (ARWR) at Strong Buy and Held Target at $60 on, Aug 8th, 2023.

Keay has made no other calls on ARWR in the last 4 months.

There are 8 other peers that have a rating on ARWR. Out of the 8 peers that are also analyzing ARWR, 2 agree with Keay's Rating of Hold. Following are those relevant analyst calls for the last 4 months

---

• Mani Foroohar of "SVB Leerink" Downgraded from Buy to Hold and Held Target at $40 on, Friday, May 12th, 2023
• Michael Ulz of "Morgan Stanley" Maintained at Hold with Increased Target to $40 on, Wednesday, May 3rd, 2023

These are the ratings of the 6 analyists that currently disagree with Keay

---

• Brendan Smith of "TD Cowen" Initiated at Buy on, Friday, July 21st, 2023
• Mayank Mamtani of "B. Riley Securities" Reiterated at Strong Buy and Held Target at $55 on, Thursday, July 20th, 2023
• Patrick Trucchio of "HC Wainwright & Co." Reiterated at Strong Buy and Held Target at $90 on, Friday, June 30th, 2023
• Edward Tenthoff of "Piper Sandler" Maintained at Buy with Increased Target to $59 on, Friday, June 2nd, 2023
• Madhu Kumar of "Goldman Sachs" Maintained at Strong Buy with Increased Target to $73 on, Wednesday, May 3rd, 2023
• David Hoang of "SMBC Nikko" Initiated at Buy and Held Target at $80 on, Wednesday, April 26th, 2023

Contributing Sources

---